Washington SB 5020: Assessing a penalty on unsupported prescription drug price increases to protect the safety, health, and economic well-being of Washington residents.

Status: By resolution, reintroduced and retained in present status. (as of 2022-01-10)

State: Washington · Session: 2021-2022 · Bill: SB 5020

Subjects: DRUGS, HEALTH CARE AUTHORITY

Sponsors: Keiser, C. Wilson, Conway, Das, Hasegawa, Kuderer, Lovelett, Robinson, Rolfes, Stanford, Van De Wege

View Washington SB 5020 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.